CRVS.US Corvus Pharmaceuticals Inc

Healthcare Biotechnology USA Stocks
10.64 USD
Close of Nov 14, 2026
6.39 26.95
Market cap
USD 898M
P/E
-
P/B
4.31x
ROE
-33.3%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is CRVS.US undervalued?

Graham number

The Graham number of Corvus Pharmaceuticals Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Corvus Pharmaceuticals Inc fundamental analysis

No fundamental analysis for Corvus Pharmaceuticals Inc yet.

Corvus Pharmaceuticals Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States. The company's lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1b/2 clinical trial for the treatment of peripheral T cell lymphoma, a…

Full company profile